ProQR Therapeutics N.V. (FRA:0PQ)

Market Cap	128.76M -45.8%
Revenue (ttm)	16.07M -12.6%
Net Income	-42.57M
EPS	-0.41
Shares Out	n/a
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	n/a
Average Volume	265
Open	1.222
Previous Close	1.238
Day's Range	1.222 - 1.222
52-Week Range	0.955 - 2.558
Beta	n/a
RSI	40.65
Earnings Date	Mar 13, 2026

About ProQR Therapeutics

ProQR Therapeutics N.V., a biotechnology company, focuses on the discovery and development of novel therapeutic medicines. The company’s products pipeline includes AX-0810 for cholestatic diseases targeting Na-taurocholate cotransporting polypeptide (NTCP); and AX-1412 for cardiovascular diseases (CVDs) targeting Beta-1,4-galactosyltransferase 1 (B4GALT1). It also develops various other early-stage research programs, including AX-1005 for undisclosed targets in CVDs; AX-2402, which focuses on Rett syndrome; AX-2911 for metabolic dysfunction-ass...

• Industry: Biological Products, Except Diagnostic Substances
• Founded: 2012
• Employees: 166
• Stock Exchange: Frankfurt Stock Exchange
• Ticker Symbol: 0PQ

Financial Performance

In 2024, ProQR Therapeutics's revenue was 19.55 million, an increase of 196.41% compared to the previous year's 6.59 million. Losses were -27.76 million, -1.27% less than in 2023.